Development Pipeline [Main table] (as of April 24, 2025)

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
Filed						
RG7446 Roche	atezolizumab Tecentriq	Relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type #	Japan	October 2024	Engineered anti-PD-L1 monoclonal antibody Antibody (IV)	–
RG6356/SRP-9001 Sarepta	delandistrogene moxeparvovec -	Duchenne muscular dystrophy (DMD) (ambulatory)	Japan	August 2024	Microdystrophin gene therapy Gene therapy (IV)	Sarepta*
RG7716 Roche	faricimab Vabysmo	Angioid streaks #	Japan	September 2024	Anti-VEGF/Anti-Ang-2 bispecific antibody Antibody (vitreous injection)	–
– Roche	mycophenolate mofetil CellCept	Refractory nephrotic syndrome #	Japan	March 2025	Immunosuppressant Small molecule (oral)	–
Phase III						
AF802/RG7853 in-house	alectinib Alecensa	Maintenance treatment of NSCLC (stage III) after chemoradiotherapy #	Global	-	ALK inhibitor Small molecule (oral)	Roche
RG7446 Roche	atezolizumab Tecentriq	NSCLC (perioperative) #	Japan	2026	Engineered anti-PD-L1 monoclonal antibody Antibody (IV)	Roche
		Muscle-invasive bladder cancer (adjuvant) #	Japan	2025		Roche
		HCC (intermediate stage) # (Avastin) #	Japan	2025		Roche
		HCC (2nd Line) # (lenvatinib or sorafenib)	Japan	-		Roche
RG6058 Roche	tiragolumab -	NSCLC (stage III) (Tecentriq) #	Japan	2025	Anti-TIGIT human monoclonal antibody Antibody (IV)	Roche
		Esophageal cancer (Tecentriq) #	Japan	2025		Roche
		HCC (1st line) (Tecentriq/Avastin)	Japan	2026		Roche

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
RG6171 Roche	giredestrant -	Breast cancer (adjuvant)	Japan	2027	SERD (Selective Estrogen Receptor Degrader) Small molecule (Oral)	Roche
		Breast cancer (1st Line) (palbociclib + letrozole)	Japan	2026		Roche
		Breast cancer (1st Line-3rd Line) (everolimus)	Japan	2026		Roche
RG7828 Roche	mosunetuzumab Lunsumio	Follicular lymphoma (2nd Line) # (lenalidomide)	Japan	2026	Anti-CD20/CD3 bispecific antibody Antibody (IV)	Roche
		Relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma # (Polivy) #	Japan	2025	Anti-CD20/CD3 bispecific antibody Antibody (SC)	Roche
		Previously untreated follicular lymphoma #	Japan	2028 and beyond	Anti-CD20/CD3 bispecific antibody Antibody (IV)	Roche
RG6026 Roche	glofitamab	Previously untreated large B-cell lymphoma (Polivy)	Japan	2028 and beyond	Anti-CD20/CD3 bispecific antibody Antibody (IV)	Roche
RG6330 Roche	divarasib -	NSCLC (2nd Line)	Japan	2027	KRAS G12C inhibitor Small molecule (Oral)	Roche
RG7159 GlycArt Biotechnology	obinutuzumab Gazyva	Lupus nephritis #	Japan	2026	Glycoengineered type II anti-CD20 monoclonal Antibody Antibody (IV)	Nippon shinyaku
		Pediatric nephrotic syndrome #	Japan	2026		Nippon shinyaku
		Extra renal lupus #	Japan	2027		Nippon shinyaku
RG6299/ASO factor B Ionis Pharmaceuticals	sefaxersen -	IgA nephropathy	Japan	2028 and beyond	antisense oligonucleotide targeting *complement factor B* mRNA Nucleic acid (SC)	Roche
RG6631 Roche	- -	Ulcerative colitis	Japan	2027	Anti-TL1A antibody Antibody (-)	Roche

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
SA237/RG6168 in-house	satralizumab Enspryng	Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) #	Global	2026	pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC)	Roche
		Autoimmune encephalitis (AIE) #	Global	2027		Roche
RG6356/SRP-9001 Sarepta	delandistrogene moxeparvovec -	Duchenne muscular dystrophy (DMD) (non-ambulatory)	Japan	2027	Microdystrophin gene therapy Gene therapy (IV)	Sarepta*
SKY59/RG6107 in-house	crovalimab PiaSky	Atypical hemolytic uremic syndrome (aHUS) #	Global	2026	Anti-C5 recycling antibody Antibody (SC)	Roche
SA237/RG6168 in-house	satralizumab Enspryng	Thyroid eye disease (TED) #	Global	2026	pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC)	Roche
RG6179 Roche	vamikibart -	Noninfectious uveitic macular edema (UME)	Japan	2026	Anti-IL-6 monoclonal antibody Antibody (vitreous injection)	Roche
Phase II/III						
GYM329/ RG6237 in-house	- -	Spinal muscular atrophy (Evrysdi)	Global	2028 and beyond	Anti-latent myostatin sweeping antibody Antibody (SC)	Roche
Phase II						
GYM329/ RG6237 in-house	- -	Facioscapulohumeral muscular dystrophy (FSHD)	Global	2028 and beyond	Anti-latent myostatin sweeping antibody Antibody (SC)	Roche

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
SA237/RG6168 in-house	satralizumab Enspryng	Duchenne muscular dystrophy (DMD) #	Global	2028 and beyond	pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC)	Roche
RG6042 Ionis Pharmaceuticals	tominersen -	Huntington's disease	Japan	-	Antisense oligonucleotide targeting *HTT* mRNA Nucleic acid (IV)	Roche
SKY59/RG6107 in-house	crovalimab PiaSky	Sickle cell disease (SCD) #	Global (excluding Japan)	2028 and beyond	Anti-C5 recycling antibody Antibody (SC)	Roche
AMY109 in-house	- -	Endometriosis	Global	-	Anti-IL-8 recycling antibody Antibody (SC)	-
Phase I/II						
RG6102 MorphoSys	trontinemab —	Alzheimer's disease	Japan	-	Anti-amyloid beta/TfR1 fusion protein Antibody (IV)	Roche
NXT007/ RG6512 in-house	- -	Hemophilia A	Global	2028 and beyond	Anti-coagulation factor IXa/X bispecific antibody Antibody (SC)	Roche
RG6321 Roche	ranibizumab (Port delivery system) -	Neovascular age-related macular degeneration	Japan	2026	Humanized anti-VEGF monoclonal antibody Fragment Fab Antibody (injection via implant)	-
		Diabetic macular edema	Japan	2026		-
RG6615 Alnylam Pharmaceuticals	zilebesiran -	Hypertension	Japan	-	RNAi therapeutic targeting angiotensinogen (AGT) RNAi (SC)	Alnylam Pharma ceuticals
Phase I						
LUNA18 in-house	paluratide -	Solid tumors	Global	-	RAS inhibitor Mid-size molecule (Oral)	-

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
GC33 in-house	codrituzumab -	HCC	Global	-	Anti-Glypican-3 humanized monoclonal antibody Antibody (IV)	-
STA551 in-house	- -	Solid tumors	Global	-	Anti-CD137 agonistic Switch antibody Antibody (IV)	-
SOF10/RG6440 in-house	- -	Solid tumors	Global	-	Anti-latent TGF-β1 monoclonal antibody Antibody (IV)	Roche
ALPS12 in-house	- -	Solid tumors	Global	-	Anti-DLL3/CD3/CD137 trispecific antibody Antibody (IV)	-
SAIL66 in-house	- -	CLDN6 positive solid tumors	Global	-	Anti-CLDN6/CD3/CD137 trispecific antibody Antibody (IV)	-
ROSE12 in-house	- -	Solid tumors	Global	-	Anti-CTLA-4 Switch antibody Antibody (IV)	-
MINT91 in-house	- -	Solid tumors	Global	-	- Small molecule (Oral)	-
RG7421 Exelixis	cobimetinib -	Solid tumors	Japan	-	MEK inhibitor Small molecule (Oral)	-
RG6026 Roche	glofitamab -	Hematologic tumors	Japan	-	Anti-CD20/CD3 bispecific antibody Antibody (IV)	-
RG6160 Roche	cevostamab -	Relapsed or refractory multiple myeloma	Japan	-	Anti-FcRH5/CD3 bispecific antibody Antibody (IV)	-
DONQ52 in-house	- -	Celiac disease	Global	-	Anti-HLA-DQ2.5/gluten peptides multispecific antibody Antibody (SC)	-
RAY121 in-house	- -	Autoimmune disease	Global	-	Anti-C1s recycling antibody Antibody (SC)	-

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Projected submission	Mode of Action Modality (Dosage form)	Partner
RG7935 Prothena	prasinezumab -	Parkinson's disease	Japan	-	Anti-α-synuclein monoclonal antibody Antibody (IV)	-
REVN24 in-house	- -	Acute diseases	Global	-	- Small molecule (IV)	-
GYM329/RG6237 In-house	- -	Obesity	Global	-	Anti-latent myostatin sweeping antibody Antibody (SC)	Roche
BRY10 In-house	- -	Chronic diseases	Global	—	- Antibody (SC)	-
RAY121 in-house	- -	-	Global	-	Anti-C1s recycling antibody Antibody (-)	-

Development Discontinued

Development code Origin	Generic name Product name	Indication # Additional indication (Combination drug)	Country/region	Development stage	Mode of Action Modality (Dosage form)	Partner
RG435 Roche	bevacizumab Avastin	Small cell lung cancer (SCLC) (1st Line) # (Tecentriq)	Japan/China	Phase III	Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody Antibody (IV)	Roche (China)

In principle, completion of first dose is regarded as pipeline entry into each phase of clinical studies. * Sarepta manages the global study including Japan

Changes from the last announcement on January 30, 2025

Oncology

- RG7446 Filed (Alveolar soft part of sarcoma) → Approved
- MINT91 Phase I (Solid tumors: development started)
- RG435 Phase III (SCLC (1st Line) (combination with RG7446): development discontinued)

Immunology

- CellCept Filed (Refractory nephrotic syndrome)
- RG6631 Phase III (Ulcerative colitis: development started)

Neuroscience

- SA237/RG6168 Phase II (DMD: development started)

Other Diseases

- RAY121 Phase I (development started)

R&D Activities

For the changes during the FY2025 (January 1 –March 31), please refer to page 4of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the three months ended March 31, 2025).”

Changes from April 1, 2025 to April 24, 2025 are as follows:

Oncology

- We started Phase I study for MINT91 for the treatment of solid tumors in April 2025.

Neuroscience

- We started Phase II study for a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody SA237/RG6168 (Product name: Enspryng) for the treatment of Duchenne muscular dystrophy (DMD) in April 2025.

Immunology

- We started global Phase III study for an anti-TL1A antibody RG6631 for the treatment of ulcerative colitis in April 2025.

Development Pipeline [Attached table] (Major Chugai originated developments licensed out to 3rd parties excluding Roche)

Development code licensee/In-house	Generic name Product name	Indication # Additional Indication (combination)	Stage Country/region	Mode of Action Modality (Dosage form)	Licensee (Granted rights)
VS-6766/CKI27	avutometinib —	KRAS-mutated recurrent LGSOC (defactinib)	Phase III/Filed* Global/U.S.	RAF/MEK clamp Small molecule (Oral)	Verastem Oncology (exclusive global license for the manufacturing, development and marketing)
			Phase II Japan		
		KRAS G12C advanced NSCLC (sotorasib±defactinib)	Phase I/II Global, U.S.		
		mPDAC (1st line) (defactinib+chemotherapy)	Phase I/II U.S.		
LY3502970/OWL833	orforglipron —	Type 2 diabetes	Phase III Global	Oral non-peptidic GLP-1 receptor agonist Small molecule (Oral)	Eli Lilly and Company (worldwide development and commercialization rights)
		Obesity	Phase III Global		
		Obstructive Sleep Apnea	Phase III Global		
AP306/EOS789	— —	Hyperphosphatemia	Phase II China	Oral inhibitor of phosphate transporters Small molecule (Oral)	Alebund (exclusive global license for the manufacturing, development and marketing)

* New Drug Application (NDA) under the accelerated approval pathway was accepted. The NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025.

Progress made in R&D activities of major Chugai originated developments licensed out to 3rd party excluding Roche during the period from January 1, 2025 to April 24, 2025 was as follows.

- In Europe, Galderma obtained regulatory approval for the anti-IL-31 receptor A humanized monoclonal antibody CIM331 (Product name in Europe: NEMLUVIO® (nemolizumab)) for moderate-to-severe atopic dermatitis and prurigo nodularis in February 2025.

Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs (As of April 24, 2025)

Development Request	Product	Indication	Development Status
Fourth development request	Xeloda*	Neuroendocrine tumor	Submitted company opinion and waiting for evaluation by committee
	Avastin	Cerebral edema induced by radiation necrosis	Submitted company opinion and waiting for evaluation by committee
	CellCept	Refractory nephrotic syndrome (frequently relapsing or steroid-dependent nephrotic syndrome)	Submitted public knowledge-based sNDA filing
	Mircera	Anemia associated with chronic kidney disease (CKD) in pediatric patients 3 months of age and older	Submitted company opinion and waiting for evaluation by committee

*Transferred the marketing authorization holder to CHEPLAPHARM K.K. as of February 1, 2024

Major Clinical Trials

Project	Expected indication	Study design	Study name	Stage	CT information
Oncology					
AF802/RG7853 (Alecensa)	Maintenance treatment of NSCLC (stage III) after chemoradiotherapy	*ALK* fusion-positive: Alecensa vs. durvalumab	HORIZON01	Phase III	NCT05170204
RG7446 (Tecentriq)	NSCLC (periadjuvant)	Chemo ± Tecentriq	IMpower030	Phase III	NCT03456063
	Muscle-invasive bladder cancer (adjuvant)	Tecentriq vs. placebo	IMvigor011	Phase III	NCT04660344
	HCC (intermediate stage)	Tecentriq + Avastin + TACE vs. TACE	TALENTACE	Phase III	NCT04803994
	HCC [2nd line]	Tecentriq + lenvatinib or sorafenib vs. lenvatinib or sorafenib	IMbrave251	Phase III	NCT04770896
RG6058 (tiragolumab)	NSCLC [stage III]	Tecentriq + RG6058 vs. durvalumab	SKYSCRAPER-03	Phase III	NCT04513925
	Esophageal cancer	Tecentriq + RG6058 vs. Tecentriq vs. placebo	SKYSCRAPER-07	Phase III	NCT04543617
	HCC (1st line)	Tecentriq + Avastin ± RG6058	IMbrave152/SKYSCRAPER-14	Phase III	NCT05904886
RG6171/SERD (giredestrant)	Breast cancer (adjuvant)	HR positive: RG6171 vs. endocrine therapy	lidERA	Phase III	NCT04961996
	Breast cancer [1st line]	HR positive: RG6171 + palbocicilib ± Letrozole	persevERA	Phase III	NCT04546009
	Breast cancer [1st line-3rd line]	HR positive: RG6171 + everolimus vs. endocrine therapy+ everolimus	evERA	Phase III	NCT05306340
RG7828	Follicular lymphoma [2nd line]	RG7828 + lenalidomide vs Rituxan + lenalidomide	CELESTIMO	Phase III	NCT04712097

Project	Expected indication	Study design	Study name	Stage	CT information
(Lunsumio)	Relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma	RG7828 + Polivy vs Rituxan + chemotherapy	SUNMO	Phase III	NCT05171647
	Previously untreated follicular lymphoma	RG7828+ lenalidomide vs. Rituxan + chemotherapy	-	Phase III (domestic)	jRCT2011240017
RG6026 (glofitamab)	Previously untreated large B-cell lymphoma	RG6026 + Polivy + Rituxan + chemotherapy vs Polivy + Rituxan + chemotherapy	SKYGLO	Phase III	NCT06047080
RG6330 (divarasib)	NSCLC [2nd line]	divarasib vs. sotorasib or adagrasib	Krascendo 1	Phase III	NCT06497556
Immunology					
RG7159 (Gazyva)	Lupus nephritis	standard treatment ± Gazyva	-	Phase III (domestic)	jRCT2011210059
	Pediatric nephrotic syndrome	Gazyva vs. MMF	INShore	Phase III	NCT05627557
	Extra renal lupus	Gazyva vs. Placebo	-	Phase III (domestic)	jRCT2071230031
RG6299 （sefaxersen）	IgA nephropathy	RG6299 vs. Placebo	IMAGINATION	Phase III	NCT05797610
RG6631	Ulcerative colitis	RG6631 vs. Placebo	Ametrine-1	Phase III	NCT06589986
Neuroscience					
SA237/RG6168 (Enspryng)	Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)	Enspryng vs. Placebo	METEOROID	Phase III	NCT05271409
	Autoimmune encephalitis (AIE)	Enspryng vs. Placebo	CIELO	Phase III	NCT05503264
GYM329/RG6237	Spinal muscular atrophy (SMA)	GYM329 ± Evrysdi	MANATEE	Phase II/III	NCT05115110
RG6356/SRP-9001 (delandistrogene moxeparvovec	Duchenne muscular dystrophy (DMD) (non-ambulatory)	RG6356 vs. Placebo	ENVISION	Phase III	NCT05881408
Hematology					
SKY59/RG6107 (PiaSky)	Atypical hemolytic uremic syndrome (aHUS)	PiaSky (single arm)	COMMUTE-a	Phase III	NCT04861259
			COMMUTE-p	Phase III	NCT04958265
Ophthalmology					
SA237/RG6168 (Enspryng)	Thyroid eye disease (TED)	Enspryng vs. Placebo	SatraGo 1/ SatraGo 2	Phase III	NCT05987423 NCT06106828

Project	Expected indication	Study design	Study name	Stage	CT information
RG6179 (vamikibart)	Noninfectious uveitic macular edema	RG6179 (single arm)	Sandcat	Phase III	NCT05642325
RG6321 (ranibizumab (Port delivery system))	Neovascular age-related macular degeneration / Diabetic macular edema	RG6321 (single arm)	-	Phase I/II (domestic)	jRCT2071210073

Clinical Trials of In-House Developed Projects

*Excluding projects listed in Major Clinical Trials of the development pipeline. Only clinical trials led by Chugai or Roche are listed.

Project	Expected indication	Stage	Enrollment as of March 31, 2025	Study start	CT information
Oncology					
LUNA18	Solid tumors	Phase I	195	October, 2021	NCT05012618
GC33	HCC	Phase I	27	November, 2008	NCT00746317
		Phase I	42	October, 2009	NCT00976170
		Phase I (domestic)	18	October, 2010	jRCT2080221218
		Phase II	185	May, 2012	NCT01507168
		Phase I	27	August, 2016	jRCT2080223270
STA551	Solid tumors	Phase Ia/Ib	160	March, 2020	2023-508764-30-00
SOF10/RG6440	Solid tumors	Phase I (domestic)	66	June, 2021	jRCT2031200407
		Phase Ib	102	October, 2023	NCT05867121
ALPS12	Solid tumors	Phase I	41	January, 2023	NCT05619744
SAIL66	CLDN6-positve solid tumors	Phase I	231	April, 2023	NCT05735366
ROSE12	Solid tumors	Phase Ia/Ib	219	June, 2023	NCT05907980
MINT91	Solid tumors	Phase I	122	April, 2025	jRCT2031240713
Immunology					
DONQ52	Celiac disease	Phase Ia/Ib	56	September, 2022	NCT05425446
		Phase Ic	56	July, 2024	ACTRN12624000316505
RAY121	Autoimmune disease	Phase I (domestic) (only healthy adults)	40	October, 2022	jRCT2071220036
		Phase Ib	144	August, 2024	jRCT2041240035
Neuroscience					
GYM329/RG6237	Facioscapulohumeral muscular	Phase II	48	March, 2023	NCT05548556

Project	Expected indication	Stage	Enrollment as of March 31, 2025	Study start	CT information
	dystrophy (FSHD)				
SA237/RG6168 (Enspryng)	Duchenne muscular dystrophy (DMD)	Phase II	50	April, 2025	NCT06450639
Hematology					
SKY59/RG6107 (PiaSky)	Sickle cell disease (SCD)	Phase IIa	90	March, 2022	NCT05075824
		Phase Ib	30	March, 2022	NCT04912869
NXT007/RG6512	Hemophilia A	Phase I/II	106	August, 2019	jRCT2080224835
		Phase I (domestic) (only healthy adults)	30	May, 2022	jRCT2031220050
		Phase I/II	60	October, 2023	NCT05987449
Other diseases					
AMY109	Endometriosis	Phase I (domestic)	100	October, 2018	jRCT2080223785
		Phase II	120	January, 2024	ISCTRN15654320
REVN24	Acute diseases	Phase I (domestic) (only healthy adults)	210	October, 2023	jRCT2071230074
BRY10	Chronic diseases	Phase I (domestic) (only healthy adults)	72	September, 2024	jRCT2051240123
RAY121	-	Phase I (only healthy adults)	36	March, 2025	2024-515151-38-00
GYM329/RG6237	Obesity	Phase I	30-36	May, 2024	-

* The number of enrollments is listed based on public information and generally refers to estimations or actual results.

FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of April 24, 2025)

Alterations	Cancer type	Relevant drugs
Activating *EGFR* alterations	NSCLC	afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, dacomitinib hydrate
EGFR exon 20 T790M alteration		osimertinib mesilate
ALK fusion genes		alectinib hydrochloride, crizotinib, ceritinib, brigatinib
ROS1 fusion genes		entrectinib
MET exon 14 skipping alterations		capmatinib hydrochloride hydrate

BRAF V600E and V600K alterations	Malignant melanoma	dabrafenib mesilate, trametinib dimethyl sulfoxide, vemurafenib, encorafenib, binimetinib
ERBB2 copy number alterations (HER2 gene amplification positive)	Breast cancer	trastuzumab (genetical recombination)
AKT1 alterations		capivasertib
PIK3CA alterations		
PTEN alterations		
KRAS/NRAS wildtype	Colorectal cancer	cetuximab (genetical recombination), panitumumab (genetical recombination)
Microsatellite instability-high		nivolumab (genetical recombination)
Microsatellite instability-high	Solid tumors	pembrolizumab (genetical recombination)
Tumor mutational burden-high		pembrolizumab (genetical recombination)
NTRK1/2/3 fusion genes		entrectinib, larotrectinib sulfate, repotrectinib
RET fusion genes		selpercatinib
BRCA1/2 alterations	Ovarian cancer	olaparib
BRCA1/2 alterations	Prostate cancer	olaparib, talazoparib tosilate
FGFR2 fusion genes	Biliary tract cancer	pemigatinib

* Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval

FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of April 24, 2025)

Alterations	Cancer type	Relevant drugs
Activating *EGFR* alterations	NSCLC	afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate
EGFR exon 20 T790M alteration		osimertinib mesilate
ALK fusion genes		alectinib hydrochloride, crizotinib, ceritinib
ROS1 fusion genes		entrectinib
MET exon 14 skipping alterations		capmatinib hydrochloride hydrate
NTRK1/2/3 fusion genes	Solid tumors	entrectinib
BRCA1/2 alterations	Prostate cancer	olaparib